Case 3: Front Line Therapy Options in ET
Experts in essential thrombocythemia review first line treatment options.
EP: 1.Case 1: Hydroxyurea-Resistant Polycythemia Vera (P. Vera)
EP: 2.Case 1: Diagnosis of P. Vera
EP: 3.Case 1: Risk Assessment in P. Vera
EP: 4.Case 1: Initial Treatment Options for Low Risk P. Vera
EP: 5.Case 1: Considerations for Cytoreductive Therapy in P. Vera
EP: 6.Case 1: Treatment Options after Hydroxyurea Failure in P. Vera
EP: 7.Case 1: Treatment Approaches for High Risk P. Vera
EP: 8.Case 1: Role of Symptomatic Improvement in Overall Outcome in MF
EP: 9.Case 2: High Risk Myelofibrosis (MF)
EP: 10.Case 2: Prognostic Models of MF
EP: 11.Case 2: Predictors of Response to Ruxolitinib in High Risk MF
EP: 12.Case 2: Safety and Efficacy of Ruxolitinib in High Risk MF
EP: 13.Case 2: Efficacy and Safety of Fedratinib in High Risk MF
EP: 14.Case 2: Considerations for Optimizing Therapy in High Risk MF
EP: 15.Case 3: Essential Thrombocythemia (ET)
EP: 16.Case 3: Risk Assessment in ET
EP: 17.Case 3: Individualized Therapy for ET
EP: 18.Case 3: Molecular Profile and Initiation of Therapy in ET
EP: 19.Case 3: Front Line Therapy Options in ET
EP: 20.Case 3: Disease Progression and Transformation in ET
Ruben Mesa, MD: Prithviraj, the guidelines offer 3 options as frontline therapy. As I like to say, there’s both the art and the science of medicine. The guidelines help provide the science. The art is which of the medicines you choose. How do you choose between those frontline options in ET?
Prithviraj Bose, MD: Hydroxyurea, pegylated interferon, and maybe even anagrelide could be considered frontline options. However, I do not use anagrelide as a frontline option. I keep it to hydroxyurea and interferon. My view thus far with interferon has been that I tend to offer it if the patient is very young, younger than 40, or if pregnancy is a consideration. Otherwise, I tend to default to Hydrea. As this panel is well aware, the leukemogenicity has never been proven. It sometimes comes up and tends to be an area of some controversy, but since it has never been proven and it is an effective, inexpensive, convenient, and safe drug, I usually go with hydroxyurea.
This transcript has been edited for clarity.
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
